How is Repatha (evolocumab) administered?
Repatha is given as an injection under the skin (subcutaneous). It comes in prefilled devices, including a prefilled pen and an on-body injector, which let patients administer the dose themselves after training.
What are the usual dosing schedules for Repatha?
Common prescribed schedules are either:
- 140 mg every 2 weeks, or
- 420 mg once every month
Your exact schedule depends on your prescribed product and dose regimen.
Where do patients inject Repatha, and how do you rotate sites?
Repatha is injected into subcutaneous tissue. Patients typically rotate injection sites to help reduce local irritation and follow the specific instructions provided with their device. Common areas for subcutaneous injections include the abdomen and thigh, and in some cases the upper arm, depending on clinician guidance and the device instructions.
What should patients do if they miss a dose?
If you miss a planned dose, take it when you can and then resume your regular schedule as directed by your prescriber or the medication instructions. Because Repatha has fixed dosing intervals (every 2 weeks vs monthly), the “missed dose” plan depends on which schedule you’re on.
Does Repatha have any administration “do’s” or “don’ts”?
Patients should generally:
- Use only the prefilled device supplied for the specific Repatha presentation.
- Follow the device directions for preparation, injection technique, and disposal.
- Avoid injecting into areas that are red, irritated, or hard to the touch.
Can Repatha be used with other cholesterol medicines?
Repatha is commonly used alongside other lipid-lowering therapies (for example, statins or ezetimibe) when additional LDL-C lowering is needed, based on the treatment plan set by the prescribing clinician.
Who typically gets Repatha, and why does administration matter?
Repatha is used to lower LDL cholesterol in patients with conditions where more aggressive LDL-C reduction is needed (such as familial hypercholesterolemia or established cardiovascular disease), and the self-injection route supports long-term adherence compared with IV therapies.
Sources
DrugPatentWatch.com: https://www.drugpatentwatch.com/